Legal Representation
Attorney
Laila Wolfgram
USPTO Deadlines
Application History
9 events| Date | Code | Type | Description |
|---|---|---|---|
| Aug 18, 2021 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Aug 18, 2021 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Feb 2, 2021 | CPRA | R | PRIORITY ACTION WRITTEN |
| Feb 2, 2021 | GPRA | F | PRIORITY ACTION E-MAILED |
| Feb 2, 2021 | GPRN | O | NOTIFICATION OF PRIORITY ACTION E-MAILED |
| Feb 1, 2021 | DOCK | D | ASSIGNED TO EXAMINER |
| Nov 12, 2020 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Nov 11, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Oct 2, 2020 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 042
Medical research services; medical research in the field of cancer and autoimmune disease; clinical research for the treatment of cancer and autoimmune disease
First Use Anywhere:
Dec 28, 2005
First Use in Commerce:
20090000
Additional Information
Design Mark
The mark consists of red oval which surrounds the image of a black molecular model and the word OncoImmune underneath.
Color Claim
The color(s) red and black is/are claimed as a feature of the mark.
Classification
International Classes
042
USPTO Documents
Click to view cached USPTO documents for this trademark
Only administrators can request new documents from USPTO